The price of Reata Pharmaceuticals Inc. (NASDAQ: RETA) closed at $42.01 in the last session, up 0.21% from day before closing price of $41.92. In other words, the price has increased by $+0.09 from its previous closing price. On the day, 1670025 shares were traded. RETA stock price reached its highest trading level at $46.89 during the session, while it also had its lowest trading level at $41.74.
We take a closer look at RETA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 8.80 and its Current Ratio is at 8.80. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Guggenheim on October 19, 2022, initiated with a Buy rating and assigned the stock a target price of $75.
SVB Leerink Downgraded its Outperform to Mkt Perform on December 09, 2021, while the target price for the stock was maintained at $35.
For the stock, the TTM Price-to-Sale (P/S) ratio is 489.21 while its Price-to-Book (P/B) ratio in mrq is 350.08.
Stock Price History:
Over the past 52 weeks, RETA has reached a high of $43.90, while it has fallen to a 52-week low of $18.47. The 50-Day Moving Average of the stock is 37.45, while the 200-Day Moving Average is calculated to be 31.06.
According to the various share statistics, RETA traded on average about 557.14K shares per day over the past 3-months and 428.52k shares per day over the past 10 days. A total of 36.54M shares are outstanding, with a floating share count of 30.57M. Insiders hold about 3.70% of the company’s shares, while institutions hold 89.30% stake in the company. Shares short for RETA as of Oct 13, 2022 were 5.34M with a Short Ratio of 7.98M, compared to 4.95M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 14.62% and a Short% of Float of 26.24%.
The company has 8 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$2.18 for the current quarter, with a high estimate of -$2.05 and a low estimate of -$2.63, while EPS last year was -$1.97. The consensus estimate for the next quarter is -$2.17, with high estimates of -$1.83 and low estimates of -$2.6.
Analysts are recommending an EPS of between -$8.18 and -$8.75 for the fiscal current year, implying an average EPS of -$8.4. EPS for the following year is -$8.3, with 8 analysts recommending between -$6.6 and -$10.69.
A total of 10 analysts have provided revenue estimates for RETA’s current fiscal year. The highest revenue estimate was $10M, while the lowest revenue estimate was $1.68M, resulting in an average revenue estimate of $3.71M. In the same quarter a year ago, actual revenue was $11.49M, down -67.70% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $25.11M in the next fiscal year. The high estimate is $38.81M and the low estimate is $6M. The average revenue growth estimate for next year is up 576.80% from the average revenue estimate for this year.